TLSA
Income statement / Annual
Last year (2025), Tiziana Life Sciences Ltd's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Tiziana Life Sciences Ltd's net income was -$18.43 M.
See Tiziana Life Sciences Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$234.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$234.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$10.28 M
|
$5.23 M
|
$8.11 M
|
$12.96 M
|
$13.21 M
|
$5.99 M
|
$2.91 M
|
$4.34 M
|
$4.67 M
|
$2.96 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$855.00 K
|
$13.21 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.77 M
|
$0.00
|
$0.00
|
$0.00
|
$855.00 K
|
$13.21 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Other Expenses |
$0.00
|
$10.57 M
|
$9.87 M
|
$1.63 M
|
$13.31 M
|
$8.82 M
|
$4.86 M
|
$3.48 M
|
$3.57 M
|
$4.33 M
|
| Operating Expenses |
$21.05 M
|
$15.79 M
|
$17.98 M
|
$14.59 M
|
$27.37 M
|
$28.03 M
|
$7.77 M
|
$7.82 M
|
$8.25 M
|
$7.29 M
|
| Cost And Expenses |
$21.28 M
|
$15.79 M
|
$17.98 M
|
$14.59 M
|
$27.37 M
|
$28.03 M
|
$7.77 M
|
$7.82 M
|
$8.25 M
|
$7.29 M
|
| Interest Income |
$19.00 K
|
$814.00 K
|
$1.15 M
|
$0.00
|
$0.00
|
$8.00 K
|
$1.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$18.00 K
|
$6.00 K
|
$10.00 K
|
$7.00 K
|
$176.00 K
|
$320.00 K
|
$73.00 K
|
$9.46 K
|
$9.00 K
|
$9.00 K
|
| Depreciation & Amortization |
$234.00 K
|
$124.00 K
|
$96.00 K
|
$51.00 K
|
$141.00 K
|
$89.76 K
|
$198.00 K
|
$12.61 K
|
$11.00 K
|
$8.00 K
|
| EBITDA |
-$21.05 M |
-$16.62 M |
-$17.14 M |
-$15.34 M |
-$26.34 M |
-$27.93 M |
-$7.58 M |
-$7.81 M |
-$8.24 M |
-$7.28 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.85 M
|
-$952.00 K
|
$742.00 K
|
-$811.00 K
|
$717.00 K
|
-$312.00 K
|
-$73.00 K
|
-$8.67 K
|
-$9.00 K
|
-$9.00 K
|
| Income Before Tax |
-$18.43 M
|
-$16.75 M
|
-$17.24 M
|
-$15.40 M
|
-$26.66 M
|
-$28.34 M
|
-$7.85 M
|
-$7.83 M
|
-$8.26 M
|
-$7.30 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$4.88 M
|
$449.00 K
|
$0.00
|
-$3.24 M
|
-$2.21 M
|
-$540.00 K
|
-$1.53 M
|
-$1.49 M
|
-$89.00 K
|
| Net Income |
-$18.43 M
|
-$11.86 M
|
-$17.69 M
|
-$15.40 M
|
-$23.42 M
|
-$26.13 M
|
-$7.31 M
|
-$6.30 M
|
-$6.77 M
|
-$7.21 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.32 |
-0.22 |
-0.34 |
-0.3 |
-0.48 |
-0.54 |
-0.11 |
-0.0924 |
-0.12 |
-0.14 |
| EPS Diluted |
-0.32 |
-0.22 |
-0.34 |
-0.3 |
-0.48 |
-0.54 |
-0.11 |
-0.0924 |
-0.12 |
-0.14 |
| Weighted Average Shares Out |
$59.14 M
|
$53.34 M
|
$50.76 M
|
$50.76 M
|
$48.97 M
|
$48.65 M
|
$68.24 M
|
$68.24 M
|
$58.49 M
|
$53.20 M
|
| Weighted Average Shares Out Diluted |
$59.14 M
|
$53.34 M
|
$50.76 M
|
$50.76 M
|
$48.97 M
|
$48.65 M
|
$68.24 M
|
$68.24 M
|
$58.49 M
|
$53.20 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
